Table 2. Clinical and biochemical characteristics, fat mass, exercise capacity, and insulin sensitivity in patients with GHD before and after GHRT and in control subjects.
| Clinical Parameters | GHD (pre-treatment) | GHRT (post-treatment) | CS | p GHD vs.GHRT | p GHD vs.CS |
|---|---|---|---|---|---|
| Gender | 4F | 4F | 4F | ns | ns |
| 6M | 6M | 6M | (n = 10/10) | (n = 10/10) | |
| Age (years) | 45.5 (n = 10) | 46.1 (n = 10) | 44.3 (n = 10) | p = 0.005 | ns |
| (32.0, 54.6) | (32.6, 55.1) | (30.6, 53.6) | (n = 10/10) | (n = 10/10) | |
| Weight (kg) | 76.3 (n = 10) | 76.5 (n = 10) | 70.5 (n = 10) | ns | ns |
| (65.0, 90.7) | (64.3, 88.3) | (58.5, 95.7) | (n = 10/10) | (n = 10/10) | |
| LBM (kg) | 50.1 (n = 10) | 48.3 (n = 9) | 49.8 (n = 10) | 0.015 | ns |
| (42.7, 61.5) | (43.0, 60.9) | (38.5, 63.8) | (n = 9/9) | (n=10/10) | |
| BMI (kg/m2) | 27.3 (n = 10) | 27.3 (n = 10) | 24.0 (n = 10) | ns | ns |
| (22.9, 29.0) | (22.3, 29.8) | (22.0, 29.2) | (n = 10/10) | (n = 10/10) | |
| Waist (cm) | 91.6 (n = 10) | 91.3 (n = 10) | 90.0 (n = 10) | ns | ns |
| (82.3, 100.3) | (81.3, 95.3) | (80.5, 97.9) | (n = 10/10) | (n = 10/10) | |
| IGF-1 (nmol/L) | 68.5 (n = 10) | 153.0 (n = 10) | 111.5 (n = 10) | p = 0.005 | p = 0.001 |
| (40.3, 87.6) | (112.0, 174.3) | (93.8, 138.3) | (n = 10/10) | (n = 10/10) | |
| Body composition | |||||
| SAT (kg) | 16.5 (n = 10) | 14.7 (n = 9) | 15.2 (n = 10) | p = 0.008 | ns |
| (14.0, 22.2) | (10.8, 21.7) | (12.2, 23.4) | (n = 9/9) | (n = 10/10) | |
| VAT (kg) | 2.37 (n = 10) | 1.96 (n = 9) | 2.57 (n = 10) | p = 0.05 | ns |
| (1.49, 3.34) | (1.09, 2.62) | (1.31, 3.37) | (n = 9/9) | (n = 10/10) | |
| Exercise capacity | |||||
| VO2max (ml/kg/min) | 36.9 (n = 10) | 42.1 (n = 10) | 39.9 (n = 10) | p = 0.005 | ns |
| (29.0, 40.1) | (37.6, 48.5) | (36.2, 46.5) | (n = 10/10) | (n = 10/10) | |
| Insulin sensitivity | |||||
| Suppression EGP from baseline (%: low insulin dose) | 59.1 (n = 9) | 40.5 (n = 8) | 38.5 (n = 10) | ns | ns |
| (25.6, 69.5) | (31.6, 52.9) | (16.7, 70.0) | (n = 8/8) | (n = 9/9) | |
| M-value (high insulin-dose) (mg/kg/min) | 7.36 (n = 9) | 7.50 (n = 10) | 7.06 (n = 10) | ns | ns |
| (6.84, 8.62) | (7.08, 7.99) | (5.28, 9.50) | (n = 9/9) | (n = 9/9) | |
Values are median and interquartile range.
GHD = growth hormone deficiency; GHRT = parameter after growth hormone replacement therapy; CS = control subjects; SAT = subcutaneous adipose tissue; VAT = visceral adipose tissue; LBM = lean body mass. Suppression EGP = suppression of endogenous glucose production = measure of hepatic insulin resistance; M-value = glucose infusion at high insulin dose = measure of peripheral insulin resistance.
Differences were evaluated by a non-parametric paired test (Wilcoxon Signed Ranks Test), between GHD patients (GHD) before and after therapy for individual patients and between GHD and CS for age/gender/waist-matched pairs, respectively.